FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366777897> ?p ?o ?g. }

• W4366777897 endingPage "383" @default.
• W4366777897 startingPage "370" @default.
• W4366777897 abstract "Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease worldwide, but disease-modifying treatments are still lacking. Poly (ADP-ribose) polymerases (PARPs) consume nicotinamide adenine dinucleotide (NAD) to repair DNA. Excessive PARP activation can deplete NAD in neurons, contributing to mitochondrial dysfunction and cell death. Mutations in the PARP-1 gene leading to lower PARP-1 levels are protective in AD. This suggests that molecular inhibitors of PARP-1 could have therapeutic potential for AD. Here, we trained a machine learning model to predict potential inhibitors of PARP-1 from FDA-approved drugs. First, we generated multimodal molecular descriptors and trained a random forest regression model. We then performed in silico screening on over 1000 compounds and generated their IC50 on PARP-1. The predicted top 3 most potent predicted inhibitors were Bryamycin, Topotecan, and Irinotecan. Bryamycin is a peptide while Topotecan and Irinotecan are small molecules. To further characterize the binding conformations of these small molecules, we performed molecular modeling to determine the binding poses and energy of Topotecan and Irinotecan. Our in silico docking results showed that Topotecan is a more potent inhibitor of PARP-1 than Irinotecan. We then analyzed the differential gene expression in the brain upon Topotecan treatment and found putative neuroprotective pathways. We conclude that Topotecan could be a potential therapeutic method against neurodegeneration through PARP-1 inhibition. Future studies are required to reveal the biochemical effect of Topotecan on PARP-1 activity and the therapeutic potential of Topotecan in animal models of AD." @default.
• W4366777897 created "2023-04-25" @default.
• W4366777897 creator A5015806093 @default.
• W4366777897 creator A5034761392 @default.
• W4366777897 date "2023-04-18" @default.
• W4366777897 modified "2023-10-05" @default.
• W4366777897 title "Topotecan and Irinotecan as potential inhibitors of PARP-1" @default.
• W4366777897 cites W1498308778 @default.
• W4366777897 cites W1839388921 @default.
• W4366777897 cites W1871475547 @default.
• W4366777897 cites W1969800514 @default.
• W4366777897 cites W1993676097 @default.
• W4366777897 cites W2014035904 @default.
• W4366777897 cites W2037337623 @default.
• W4366777897 cites W2044358936 @default.
• W4366777897 cites W2049028195 @default.
• W4366777897 cites W2059122356 @default.
• W4366777897 cites W2085413999 @default.
• W4366777897 cites W2088175135 @default.
• W4366777897 cites W2112896415 @default.
• W4366777897 cites W2117049355 @default.
• W4366777897 cites W2165308870 @default.
• W4366777897 cites W2166931288 @default.
• W4366777897 cites W2230121964 @default.
• W4366777897 cites W2292755321 @default.
• W4366777897 cites W2318680930 @default.
• W4366777897 cites W2507983749 @default.
• W4366777897 cites W2725171488 @default.
• W4366777897 cites W2770191803 @default.
• W4366777897 cites W2777416523 @default.
• W4366777897 cites W2791355014 @default.
• W4366777897 cites W2908412431 @default.
• W4366777897 cites W2944954104 @default.
• W4366777897 cites W2972368830 @default.
• W4366777897 cites W2989646929 @default.
• W4366777897 cites W3000075214 @default.
• W4366777897 cites W3006045662 @default.
• W4366777897 cites W3048989216 @default.
• W4366777897 cites W3084114043 @default.
• W4366777897 cites W3088524696 @default.
• W4366777897 cites W3170458329 @default.
• W4366777897 cites W3174624813 @default.
• W4366777897 cites W4224234680 @default.
• W4366777897 cites W4256701510 @default.
• W4366777897 cites W4282916470 @default.
• W4366777897 doi "https://doi.org/10.54097/hset.v45i.7582" @default.
• W4366777897 hasPublicationYear "2023" @default.
• W4366777897 type Work @default.
• W4366777897 citedByCount "0" @default.
• W4366777897 crossrefType "journal-article" @default.
• W4366777897 hasAuthorship W4366777897A5015806093 @default.
• W4366777897 hasAuthorship W4366777897A5034761392 @default.
• W4366777897 hasBestOaLocation W43667778971 @default.
• W4366777897 hasConcept C104317684 @default.
• W4366777897 hasConcept C121608353 @default.
• W4366777897 hasConcept C126322002 @default.
• W4366777897 hasConcept C147897179 @default.
• W4366777897 hasConcept C181199279 @default.
• W4366777897 hasConcept C182979987 @default.
• W4366777897 hasConcept C2775905019 @default.
• W4366777897 hasConcept C2776694085 @default.
• W4366777897 hasConcept C2776925932 @default.
• W4366777897 hasConcept C2779134260 @default.
• W4366777897 hasConcept C2779138821 @default.
• W4366777897 hasConcept C2779682216 @default.
• W4366777897 hasConcept C2779962180 @default.
• W4366777897 hasConcept C2780259306 @default.
• W4366777897 hasConcept C2781209748 @default.
• W4366777897 hasConcept C2781312401 @default.
• W4366777897 hasConcept C526805850 @default.
• W4366777897 hasConcept C54355233 @default.
• W4366777897 hasConcept C55493867 @default.
• W4366777897 hasConcept C71924100 @default.
• W4366777897 hasConcept C82381507 @default.
• W4366777897 hasConcept C86803240 @default.
• W4366777897 hasConcept C98274493 @default.
• W4366777897 hasConceptScore W4366777897C104317684 @default.
• W4366777897 hasConceptScore W4366777897C121608353 @default.
• W4366777897 hasConceptScore W4366777897C126322002 @default.
• W4366777897 hasConceptScore W4366777897C147897179 @default.
• W4366777897 hasConceptScore W4366777897C181199279 @default.
• W4366777897 hasConceptScore W4366777897C182979987 @default.
• W4366777897 hasConceptScore W4366777897C2775905019 @default.
• W4366777897 hasConceptScore W4366777897C2776694085 @default.
• W4366777897 hasConceptScore W4366777897C2776925932 @default.
• W4366777897 hasConceptScore W4366777897C2779134260 @default.
• W4366777897 hasConceptScore W4366777897C2779138821 @default.
• W4366777897 hasConceptScore W4366777897C2779682216 @default.
• W4366777897 hasConceptScore W4366777897C2779962180 @default.
• W4366777897 hasConceptScore W4366777897C2780259306 @default.
• W4366777897 hasConceptScore W4366777897C2781209748 @default.
• W4366777897 hasConceptScore W4366777897C2781312401 @default.
• W4366777897 hasConceptScore W4366777897C526805850 @default.
• W4366777897 hasConceptScore W4366777897C54355233 @default.
• W4366777897 hasConceptScore W4366777897C55493867 @default.
• W4366777897 hasConceptScore W4366777897C71924100 @default.
• W4366777897 hasConceptScore W4366777897C82381507 @default.
• W4366777897 hasConceptScore W4366777897C86803240 @default.

• next